HER2 Biology: Driving Next-Generation Cancer Therapies

HER2 Biology: Driving Next-Generation Cancer Therapies

Understanding HER2 biology is crucial for developing next-generation cancer treatments. This article explores how advancements in HER2 research are leading to more targeted and effective therapies. For pharma stakeholders, the HER2 axis now represents one of the most commercially consequential and scientifically active targets in oncology, driven by expanding patient populations, ADC platform competition, and diagnostic reclassification that is reshaping market access strategies across multiple tumor types.

Key Takeaways

• HER2 biology is a critical target in oncology, driving innovation in diagnostics and therapeutics.
• Next-generation treatments use a deeper understanding of HER2 signaling pathways and resistance mechanisms.
• Pharmaceutical companies must adapt R&D and commercial strategies to capitalize on emerging HER2-targeted opportunities.
• The redefinition of HER2-low disease has unlocked a patient population roughly three times larger than HER2-amplified cancer alone.
• Integrated diagnostic-therapeutic development is becoming a structural competitive advantage in the HER2 space.

What Is the Evolving Landscape of HER2 Biology?

HER2 (human epidermal growth factor receptor 2) was first identified as an oncogenic driver in breast cancer in the 1980s, when researchers at Genentech and collaborating institutions demonstrated that ERBB2 amplification correlated with aggressive disease and poor prognosis. That discovery catalyzed a generation of targeted therapies beginning with trastuzumab, which the FDA approved in 1998 for metastatic HER2-positive breast cancer. Early foundational studies established the paradigm that receptor tyrosine kinases could serve as druggable oncology targets.

Since then, understanding of HER2 biology has deepened considerably. HER2 is now recognized not merely as an amplified receptor but as a signaling hub that dimerizes preferentially with HER3 to activate the PI3K/AKT and RAS/MAPK cascades, driving proliferation, survival, and metastasis. Importantly, HER2 expression is heterogeneous, ranging from high-amplified clones to low-level expression across multiple tumor types including gastric, colorectal, non-small cell lung, and urothelial cancers. This heterogeneity has profound implications: patients with HER2-low tumors (IHC 1+ or IHC 2+/ISH-negative) were historically excluded from HER2-targeted trials, yet recent data suggest they may benefit from novel modalities.

How Are Next-Generation HER2-Targeted Therapies Reshaping Treatment?

The current wave of innovation extends well beyond monoclonal antibodies and tyrosine kinase inhibitors. Antibody-drug conjugates (ADCs) have emerged as the most commercially significant advancement. Trastuzumab deruxtecan (Enhertu), developed by Daiichi Sankyo and AstraZeneca, demonstrated unprecedented activity in HER2-low metastatic breast cancer in the DESTINY-Breast04 trial, triggering a paradigm shift in how the field defines "HER2-positive" disease. The FDA approved its HER2-low indication in August 2022, and sales exceeded $2.5 billion in the most recent fiscal year, underscoring the commercial magnitude of expanding the addressable population.

Bispecific antibodies represent another promising modality. Zanidatamab, a biparatropic anti-HER2 antibody from Jazz Pharmaceuticals and BeiGene, targets two distinct HER2 epitopes simultaneously, potentially overcoming resistance that develops against single-epitope antibodies. Phase III data in HER2-amplified biliary tract cancer showed meaningful response rates, and the companies filed a BLA with the FDA in 2024. Novel small-molecule HER2 inhibitors, including poziotinib and tucatinib, address specific resistance mutations such as HER2 exon 20 insertions found in non-small cell lung cancer, a population with historically limited options.

How Are Diagnostics Advancing HER2 Stratification?

Accurate HER2 testing has always been the gatekeeper for targeted therapy, but the diagnostic framework is evolving rapidly. Traditional IHC and FISH assays remain standard, yet the DESTINY-Breast04 results exposed significant inter-laboratory variability in scoring HER2-low status. The FDA's guidance on companion diagnostics emphasizes the need for standardized, validated assays aligned with specific therapeutic indications.

Next-generation sequencing (NGS) platforms now detect ERBB2 amplification, mutations, and co-occurring alterations simultaneously, enabling more precise patient selection. Liquid biopsy approaches, such as circulating tumor DNA assays, are gaining traction for monitoring HER2 status dynamically, particularly in metastatic settings where tissue biopsies are impractical. Emerging biomarkers such as HER2 extracellular domain shedding levels and phospho-HER2 expression may further refine patient stratification, identifying those most likely to respond to specific therapeutic modalities.

What Are the Commercial Implications for Pharma Strategy?

The HER2 space is intensely competitive, and the strategic calculus has shifted. The success of trastuzumab deruxtecan demonstrated that redefining patient populations, moving from HER2-positive to HER2-low, can unlock billions in incremental revenue. Companies now invest heavily in ADC platforms, with over 20 HER2-directed ADCs in clinical development globally, according to Cortellis data.

R&D investment decisions must account for the shrinking window of differentiation. First-generation HER2 assets face biosimilar erosion; trastuzumab biosimilars have compressed pricing in most markets. Novel mechanisms, including bispecifics, small molecules targeting resistance mutations, and combination regimens, offer defensible differentiation. Market access strategies must also adapt: payers increasingly require companion diagnostic concordance and real-world evidence of benefit across HER2 expression levels. Companies that integrate diagnostic development alongside therapeutic programs, as Daiichi Sankyo did with Enhertu, secure a structural commercial advantage.

What Remains Unmet in HER2-Targeted Treatment?

Despite remarkable progress, significant challenges persist. Acquired resistance to ADCs remains common, driven by altered intracellular trafficking, payload efflux, and downstream pathway reactivation. Brain metastases, present in up to 50% of HER2-positive metastatic breast cancer patients, remain difficult to penetrate with large-molecule therapies, though tucatinib has shown CNS activity.

Patients with HER2-mutant (non-amplified) cancers represent an underserved population where response rates to current HER2-targeted agents remain modest. Combination strategies, pairing HER2-directed agents with immune checkpoint inhibitors, CDK4/6 inhibitors, or PI3K inhibitors, are under active investigation across multiple tumor types. AstraZeneca's recent SEC filings highlight the company's ongoing investment in pan-tumor evaluations for trastuzumab deruxtecan, potentially expanding the addressable population further into endometrial, colorectal, and other histologies.

Personalized medicine approaches, matching specific HER2 alterations to optimal therapeutic modalities, represent the next frontier. Adaptive trial designs and real-world data infrastructure will be essential for generating the evidence base to support these strategies. Companies that solve the resistance problem and establish clear diagnostic-therapeutic pairings across HER2 expression levels will capture disproportionate value in the next phase of competition.

Frequently Asked Questions

Related coverage

• AstraZeneca's Imfinzi and Imjudo: A Breakthrough in Liver Cancer Treatment
• Johnson & Johnson's Erleada: A Game Changer in Prostate Cancer Treatment
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data